Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Luca Boscolo BieloMatteo RepettoEdoardo CriminiCarmen BelliElisabetta SetolaGabriella ParmaNicola FuscoMassimo BarberisElena Guerini RoccoAntonio MarraNicoletta ColomboCurigliano GiuseppePublished in: The oncologist (2024)
uLMS displays a significant frequency of somatic BRCA2alt homDel. Considering their dismal prognosis, further investigation is warranted to test the use of PARPi in uLMS, and particularly in the setting of BRCA1/2 alterations.